Total Credits: 1 including 1 AOA Category 1-A Credit(s)
Immunotherapy in cancer has uncovered extraordinary advances in disease response and survival, far beyond that seen with traditional chemotherapy. With an estimated 16 million cancer survivors today and 30 million projected by 2040, we are enabling an unprecedented number of cancer survivors. What is not yet known is how immunotherapy fully impacts survivorship, given the very different side effect profile seen.
The nature, timing, and duration of immune-related side effects has created an entirely new science of patient management. Extending far beyond oncology, patient care needs often require other specialty input, from Primary Care, Endocrinology, Cardiology, Gastroenterology, and Rheumatology. However, indirect measures of outcome (health resource utilization, patient-reported outcomes, financial toxicity) are presently understudied in this rapidly growing patient cohort.
Learning Objectives:
1. Understand the unique side effect profile and care needs of cancer patients treated with immunotherapy.
2. Identify knowledge and practice gaps in cancer care as it relates to immunotherapy.
3. Apply knowledge to create institutional best practices and develop patient-centered quality initiatives.
Disclosures: None Reported
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Osteopathic Physicians and Surgeons of California (OPSC) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
Grievance Policy: OPSC strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to OPSC, by calling the OPSC Office at 916-822-5246 or by email to opsc@opsc.org.
| Understanding Side Effects of Chemotherapy.pdf (3.00 MB) | 54 Pages | Available after Purchase |
Dr. Morganna Freeman is a skin cancer specialist & Medical Director of Community & Affiliate Practice at City of Hope, an internationally recognized Comprehensive Cancer Center. In her care of patients with advanced cancer, she focuses on a personalized immune therapy approach, and has authored several articles & book chapters on this subject. In addition to her scientific interests, she is a devoted public health advocate with a special focus on preventing skin cancer in teens & young adults, and an honored recipient of the 2018 Melanoma Research Foundation Humanitarian Award.
She completed Internal Medicine training & Chief Residency at the University of Florida and Hematology/Oncology fellowship at H Lee Moffitt Cancer Center. A Fellow of the American College of Physicians, she is dual board-certified in Medical Oncology & Internal Medicine, and completed a formal health policy fellowship followed by a 3-year tenure with the ASCO Government Relations Committee.
A rising physician leader, Dr. Freeman contributes regularly as an invited speaker, serves on cancer advisory boards, and is a skilled health policy analyst. She currently serves on the ASCO Delegation to the American Medical Association and was most recently appointed as Editor of State of Cancer Care in America publications in the Journal of Oncology Practice.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|